144 related articles for article (PubMed ID: 16618728)
1. Targeting oncogenes to improve breast cancer chemotherapy.
Christensen LA; Finch RA; Booker AJ; Vasquez KM
Cancer Res; 2006 Apr; 66(8):4089-94. PubMed ID: 16618728
[TBL] [Abstract][Full Text] [Related]
2. Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer.
Boulware SB; Christensen LA; Thames H; Coghlan L; Vasquez KM; Finch RA
Mol Carcinog; 2014 Sep; 53(9):744-52. PubMed ID: 23681918
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV
Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
5. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny GE; Pegram MD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
[TBL] [Abstract][Full Text] [Related]
7. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
8. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
9. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.
Carbone GM; McGuffie E; Napoli S; Flanagan CE; Dembech C; Negri U; Arcamone F; Capobianco ML; Catapano CV
Nucleic Acids Res; 2004; 32(8):2396-410. PubMed ID: 15121897
[TBL] [Abstract][Full Text] [Related]
10. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
[TBL] [Abstract][Full Text] [Related]
12. Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines.
Modrak DE; Leon E; Goldenberg DM; Gold DV
Mol Cancer Res; 2009 Jun; 7(6):890-6. PubMed ID: 19531570
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of transcription of the human c-myc protooncogene by intermolecular triplex.
Kim HG; Reddoch JF; Mayfield C; Ebbinghaus S; Vigneswaran N; Thomas S; Jones DE; Miller DM
Biochemistry; 1998 Feb; 37(8):2299-304. PubMed ID: 9485376
[TBL] [Abstract][Full Text] [Related]
14. HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.
Watanabe M; Sheriff S; Lewis KB; Tinch SL; Cho J; Balasubramaniam A; Kennedy MA
Cancer Lett; 2012 Feb; 315(1):18-27. PubMed ID: 22036895
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
16. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
17. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.
Smith JA; Brown J; Martin MC; Ramondetta LM; Wolf JK
Gynecol Oncol; 2004 Jan; 92(1):314-9. PubMed ID: 14751176
[TBL] [Abstract][Full Text] [Related]
18. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance.
Hernández-Vargas H; Rodríguez-Pinilla SM; Julián-Tendero M; Sánchez-Rovira P; Cuevas C; Antón A; Ríos MJ; Palacios J; Moreno-Bueno G
Breast Cancer Res Treat; 2007 Apr; 102(2):157-72. PubMed ID: 17039268
[TBL] [Abstract][Full Text] [Related]
20. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
